0001557746false00015577462021-07-232021-07-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2021

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37581

46-0571712

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

640 Lee Road, Suite 200

Wayne, PA 19087

(Address of principal executive offices, including zip code)

(484) 324-7933

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

 

 

 

 

 

Title of Each Class:

    

Trading Symbol(s)

    

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

 

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.02 Termination of a Material Definitive Agreement.

On July 23, 2021, Aclaris Therapeutics, Inc. (the “Company”) repaid in full the $11.0 million borrowed under the Loan and Security Agreement, dated as of March 30, 2020, by and among the Company, Confluence Discovery Technologies, Inc. (together with the Company, the “Borrowers”) and Silicon Valley Bank.  In addition, the Company paid (i) accrued and unpaid interest of approximately $45,000, (ii) a final payment fee of $550,000 and (iii) a prepayment fee of $120,000.  Following this repayment, all of the Borrowers’ obligations under the Loan and Security Agreement are deemed to be terminated, except as set forth in the agreement.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

ACLARIS THERAPEUTICS, INC.

By:

/s/ Frank Ruffo

Date: July 26, 2021

Frank Ruffo

Chief Financial Officer

3

Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Aclaris Therapeutics Charts.
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Aclaris Therapeutics Charts.